Results 251 to 260 of about 77,108 (288)

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Nature Medicine, 2022
Robyn P M Saw, Ellen H W Kapiteijn, Astrid A M Van Der Veldt   +2 more
exaly   +2 more sources

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Lancet, The, 2021
Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto   +2 more
exaly   +2 more sources

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

New England Journal of Medicine, 2010
F Stephen Hodi, David F Mcdermott, Caroline Robert   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

Nature Reviews Drug Discovery, 2021
Alan Korman Korman, Sarah C Garrett-Thomson, Nils Lonberg   +2 more
exaly   +2 more sources

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Nature Medicine, 2023
The combination of neoadjuvant nivolumab, ipilimumab and chemotherapy showed promising efficacy in patients with resectable non-small cell lung cancer, with higher tumor immune cell infiltration and tertiary lymphoid structures after treatment compared ...
Tina Cascone, Sreyashi Basu, Ansam Sinjab   +2 more
exaly   +2 more sources

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

Nature Medicine, 2023
Ari VanderWalde, Katie M Campbell, Philip O Scumpia   +2 more
exaly   +2 more sources

Ipilimumab

Reactions Weekly, 2015
  +12 more sources

Ipilimumab

Drugs, 2011
Ipilimumab (Yervoy®) is an anti-cytotoxic T-lymphocyte antigen (CTLA)-4 monoclonal antibody that has been approved in the US for the first- or second-line treatment of patients with malignant melanoma. In the EU, it is awaiting approval as second-line therapy for melanoma. Ipilimumab blocks the effects of the negative T-cell regulator CTLA-4, which may
Fiona, Cameron, Glenn, Whiteside, Caroline, Perry   +2 more
openaire   +2 more sources

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Journal of Clinical Oncology, 2021
PURPOSE Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that ...
H. Lenz, E. Van Cutsem, Maria Luisa Limon, K. Wong, A. Hendlisz, M. Aglietta, P. García-Alfonso, B. Neyns, G. Luppi, D. Cardin, T. Dragovich, U. Shah, S. Abdullaev, J. Gricar, J. Ledeine, M. Overman, S. Lonardi   +16 more
semanticscholar   +1 more source

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

Journal of Clinical Oncology, 2023
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
C. Robert, M. Carlino, C. McNeil, A. Ribas, J. Grob, J. Schachter, M. Nyakas, D. Kee, T. Petrella, A. Blaustein, M. Lotem, A. Arance, A. Daud, O. Hamid, J. Larkin, James Anderson, C. Krepler, Dmitri O. Grebennik, G. Long   +18 more
semanticscholar   +1 more source